Paras Vakharia, MD
Dermatology · Chicago, ILNPI 1447756473
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,953 of the $9,815 with a category attached, or 81.0%. Sanofi accounts for 90.2% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $9,080, more than ten times the $451 reported in 2023.
Across 24 payments — averaging $408.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$9K
- Johnson & Johnson$765
- AbbVie$136
- Janssen Scientific Affairs, LLC$47
- Lilly USA, LLC$16
Across 13 payments — averaging $9565.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$68K
- Janssen Research & Development, LLC$45K
- AbbVie$11K
What the payments were for
- Consulting fees$7,95381%
- Travel & lodging$6987%
- Food & beverage$1,06911%
- Education$951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $8,850 |
| Johnson & Johnson | 11 | $765 |
| AbbVie | 3 | $136 |
| Janssen Scientific Affairs, LLC | 2 | $47 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,815 in reported general payments places this provider in the 80th percentile of 606 dermatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 99 | $353,108 |
| Skyrizi PenRisankizumab-Rzaa | 15 | $278,057 |
| Humira(Cf) PenAdalimumab | 20 | $130,682 |
| OtezlaApremilast | 17 | $108,731 |
| Dupixent SyringeDupilumab | 21 | $77,650 |
| OpzeluraRuxolitinib Phosphate | 11 | $21,937 |
| Clobetasol Propionate | 117 | $5,652 |
| Tacrolimus | 43 | $3,109 |
| Triamcinolone Acetonide | 265 | $2,717 |
| Doxycycline Monohydrate | 67 | $2,256 |
| Clindamycin Phosphate | 60 | $2,120 |
| Ketoconazole | 143 | $2,109 |
| Fluorouracil | 24 | $1,971 |
| Fluocinolone Acetonide | 23 | $1,641 |
| Calcipotriene | 11 | $1,519 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Chicago
- Raj ChovatiyaChicago$3.6M
- Peter LioChicago$2.4M
- Elizabeth KiracofeChicago$1.6M
- Carolyn JacobChicago$566K
- Walter LiszewskiChicago$414K
- Omer IbrahimChicago$313K
- Caroline RobinsonChicago$308K
- Smita AggarwalChicago$214K
- Tracee BlackburnChicago$180K
- Faiyaaz KalimullahChicago$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.